证券代码：688329 证券简称：艾隆科技 公告编号：2023-036 苏州艾隆科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司已于 2023 年 4 月 21 日披露公司 2022 年年度报告；于 2023 年 4 月 28 日披露公司 2023 年第一季度报告。为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 6 月 21 日（星期三）下午 14:00-15:00 举行 2022 年度暨 2023 年第一季度业绩说明会， 就投资者关心的问题进行交流，欢迎广大投资者积极参与。 本次业绩说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 6 月 21 日(星期三)下午 14:00-15:00 会 ...

2023 年第一季度报告 证券代码：688329 证券简称：艾隆科技 苏州艾隆科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 (一)公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (二)公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 (三)第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (四)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 51,051,516.10 | 18.42 | | 归属于上市公司股东的净利润 | | 2,551,313.76 | 不适用 | | 归属于上市公司股东的扣除非 | | ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling approximately 37.73 million RMB, which represents 63.50% of the net profit attributable to shareholders for 2022[6]. - The total cash dividend for the year, including share repurchases, amounts to approximately 65.02 million RMB[6]. - The company repurchased shares totaling approximately 27.29 million RMB during the year, which is considered part of the cash dividend distribution[6]. Financial Performance - The company's operating revenue for 2022 was CNY 477,351,671.87, representing a year-on-year increase of 22.61% compared to CNY 389,321,010.94 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 102,397,709.15, which is a 7.12% increase from CNY 95,587,569.27 in 2021[24]. - The net cash flow from operating activities significantly increased by 158.40% to CNY 102,717,493.62 from CNY 39,751,602.03 in 2021[24]. - The total assets at the end of 2022 reached CNY 1,412,933,049.50, marking a 23.97% increase from CNY 1,139,692,222.35 in 2021[24]. - The basic earnings per share for 2022 was CNY 1.33, slightly up from CNY 1.32 in 2021, reflecting a 0.76% increase[25]. - The weighted average return on equity decreased to 12.38% in 2022, down by 1.32 percentage points from 13.70% in 2021[25]. Research and Development - The company's R&D expenditure as a percentage of operating revenue was 9.46% in 2022, down from 10.17% in 2021, indicating a decrease of 0.71 percentage points[25]. - R&D investment totaled 45.14 million yuan, accounting for 9.46% of sales revenue, with 942 patents applied and 409 patents granted by the end of 2022[37]. - The total R&D investment for the year was approximately ¥45.14 million, accounting for 9.46% of total revenue, a decrease of 0.71 percentage points compared to the previous year[82]. Market and Product Development - The company is focusing on the intelligent management of medical supplies, with products including smart pharmacies, smart wards, and smart logistics[42]. - The company is actively developing new products and sales strategies in the automated pharmacy and smart ward sectors[36]. - The company is committed to continuous innovation in its automation pharmacy offerings to meet evolving healthcare demands[52]. - The company is focused on developing new products and technologies to expand its market presence in the automation pharmacy sector[52]. Risk Management - The company has detailed various risks and countermeasures in its report, which can be found in the management discussion section[4]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the report[9]. - The company faces risks related to market expansion, including the potential weakening of existing customer demand penetration and challenges in acquiring new customers and markets[103]. - The company must continuously innovate and develop new products to maintain high profitability, as failure to do so may adversely affect operational performance[104]. Governance and Compliance - The company emphasizes investor communication and information disclosure, ensuring compliance with legal regulations and protecting shareholder rights[41]. - The board consists of 9 members, including 3 independent directors, ensuring compliance with governance regulations[173]. - The company has established a supervisory board with 3 members, including a staff representative, to ensure effective oversight of operations and financial conditions[174]. - The company adheres to legal and regulatory requirements in its governance practices, maintaining high standards to protect shareholder interests[173]. Strategic Investments and Acquisitions - The company acquired 30% of Suzhou Aijie Medical Technology Co., increasing its ownership to 100%[130]. - The company completed the establishment of Ailong Technology (Chuzhou) Co., Ltd., acquiring 100% equity from previous shareholders[147]. - The company plans to invest in the Chuzhou Medical and Health Industry Base Project, with strategic agreements approved by the board[146]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 500 million yuan allocated for potential deals[186]. Future Outlook - The company plans to expand its product line in the medical device sector, focusing on automation and software solutions[30]. - The company aims to leverage the trend of "smart hospital construction" to enhance its market position[30]. - Future outlook remains positive, with expectations of recovering market demand and increased profitability[182]. - The company plans to enhance its digital marketing efforts, aiming for a 30% increase in online sales channels[186].

2022 年第三季度报告 证券代码：688329 证券简称：艾隆科技 苏州艾隆科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 136,021,808.65 | 76.88 | 302,015,219.68 | 45.64 | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[13]. - The company has set a revenue target of RMB 1.2 billion for the full year 2022, indicating an expected growth of 15% compared to 2021[13]. - The company's operating revenue for the first half of the year reached ¥165,993,411.03, an increase of 27.23% compared to the same period last year[19]. - Net profit attributable to shareholders increased by 62.32% year-on-year, amounting to ¥30,212,509.22[19]. - The company achieved a revenue of 166 million RMB in the first half of 2022, representing a year-on-year growth of 27.23%[80]. - The net profit attributable to shareholders reached 30.21 million RMB, marking a 62.32% increase compared to the same period last year[80]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[130]. - The total comprehensive income for the first half of 2022 was CNY 30,376,985.88, compared to CNY 15,893,862.74 in the same period last year[180]. User Growth - User data showed an increase in active users to 1.2 million, up from 1 million in the same period last year, marking a growth of 20%[13]. - User data showed a growth in active users, reaching 5 million, which is a 20% increase compared to the previous year[128]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[130]. Product Development and Innovation - New product launches included a state-of-the-art medical device that is expected to generate an additional RMB 100 million in revenue by the end of 2022[13]. - The company is actively expanding into new application areas beyond its current focus on pharmaceuticals and medical supplies[26]. - The company has developed a series of automated pharmacy products for emergency departments, including rapid dispensing machines and intelligent storage cabinets, enhancing drug management efficiency and reducing patient wait times[29]. - The company is currently developing an integrated automated pharmacy system capable of processing over 6,000 prescriptions daily, which is now in the industrialization phase[61]. - The company is also working on a personalized Chinese medicine preparation system, which is a domestic first and is currently in the product development enhancement stage[62]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[128]. - New product launches are expected to contribute an additional 300 million in revenue by the end of the fiscal year[130]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2022[13]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 5% market share in each[128]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[130]. Research and Development - Research and development expenses increased to RMB 50 million, accounting for 10% of total revenue, reflecting a commitment to innovation[13]. - The total R&D investment for the period was approximately ¥18.76 million, representing a 5.55% increase compared to the previous year[64]. - Research and development expenses increased by 5.55% to ¥18,758,770.97, reflecting the company's commitment to innovation[98]. - The company has developed 8 core key technologies related to intelligent management of medical materials, with a total of 176 authorized patents[61]. - The company has applied for a total of 853 patents, with 399 patents granted as of the report date[81]. Strategic Acquisitions - The company has completed a strategic acquisition of a local competitor for RMB 200 million, aimed at enhancing its market share[13]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 300 million allocated for potential deals[128]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of acquiring two companies by the end of the year[130]. Operational Efficiency - The company plans to implement a new digital marketing strategy to increase customer engagement and drive sales growth[13]. - The company has set a target to reduce operational costs by 10% through efficiency improvements in the supply chain[128]. - The management emphasized the importance of compliance with regulatory requirements to avoid any potential legal issues in the future[128]. Financial Management - The company has received government support for its "integrated smart pharmacy service upgrade project," recognized as a benchmark demonstration project[81]. - The company utilized RMB 160,000,000 of raised funds for supplementary working capital, indicating a strategic move to enhance liquidity[145]. - The total amount of guarantees provided by the company, excluding guarantees to subsidiaries, is 7,000,000.00 RMB, which accounts for 0.87% of the company's net assets[141]. - The cumulative amount of funds raised through the initial public offering is 324,433,000.00 RMB, with a net amount of 274,376,492.52 RMB after deducting issuance costs[144]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions and regulatory changes, which could impact future performance[13]. - The company faces risks related to core technology and personnel turnover, which could impact product development and operational efficiency[85]. - The company faces risks related to changes in government subsidy policies, which could adversely affect its operating performance and profitability[96]. - The company acknowledges the risk of industry competition intensifying as more capital, talent, and technology enter the market[85]. Shareholder and Governance - The board of directors confirmed that there are no significant non-operating fund occupations by controlling shareholders[13]. - The company has established a long-term incentive mechanism to align the interests of shareholders, the company, and employees[82]. - The company has made commitments regarding share repurchase and measures to avoid dilution of immediate returns[134]. - The company has committed to ensuring that any share reductions after the lock-up period will not be below the IPO price[126].

Financial Performance - The company's operating revenue for 2021 was approximately RMB 389.32 million, representing a year-on-year increase of 25.60% compared to RMB 309.98 million in 2020[24]. - The net profit attributable to shareholders of the listed company increased by 33.40% year-on-year to approximately RMB 95.59 million, up from RMB 71.66 million in 2020[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 42.20% year-on-year to approximately RMB 88.91 million[24]. - The total assets of the company increased by 43.18% year-on-year to approximately RMB 1.14 billion, up from RMB 795.96 million in 2020[25]. - The net assets attributable to shareholders of the listed company increased by 76.31% year-on-year to approximately RMB 803.13 million[25]. - The basic earnings per share for 2021 was RMB 1.32, a 6.45% increase from RMB 1.24 in 2020[26]. - The company's gross profit margin for the main business was 60.16%, which increased by 0.73 percentage points year-on-year[113]. - The revenue from the automation pharmacy segment was CNY 279,202,574.01, with a gross profit margin of 64.35%, showing a decrease of 1.25 percentage points[113]. - The company achieved a total R&D investment of ¥39,611,447.29 in the current year, representing a 22.86% increase compared to ¥32,242,358.85 in the previous year[83]. Cash Flow and Dividends - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling 38.6 million yuan, which represents 40.38% of the net profit attributable to shareholders for 2021[5]. - The net cash flow from operating activities decreased by 66.09% year-on-year to approximately RMB 39.75 million, primarily due to an increase in advance payments for orders[27]. - The company’s cash flow must meet operational and developmental needs to implement cash dividends[194]. - The company will conduct profit distribution at least once a year, subject to meeting specific conditions such as profitability and positive retained earnings[194]. - The company has established a stable profit distribution policy, ensuring reasonable returns for investors while maintaining normal operations and long-term development[193]. Research and Development - The research and development expenditure accounted for 10.17% of operating revenue, slightly down from 10.40% in 2020[26]. - The company applied for 830 patents and obtained 372 patents by the end of 2021, enhancing its core competitiveness through innovation[39]. - The company has developed 8 core key technologies, with a total of 161 authorized invention patents, enhancing its capabilities in smart medical management[77]. - The company is currently testing an AI-based empty bottle recognition system for anesthesia drugs, which is in the trial production stage and aims to enhance safety in operating rooms[87]. - The company is focusing on expanding its market presence through innovative products and technologies, aiming for significant growth in the healthcare sector[85]. Market and Industry Outlook - The medical equipment industry is expected to accelerate growth starting in 2022, driven by the ongoing development of new medical infrastructure since 2020[41]. - The company is positioned to benefit from increasing hospital numbers and rising government healthcare spending, which are driving industry demand[150]. - The healthcare infrastructure development is expected to accelerate growth in the medical equipment industry starting from 2022, providing opportunities for the company[151]. - The company plans to expand its market presence by entering new regions and increasing its product offerings in 2022[164]. - Future guidance suggests a revenue growth target of 10-15% for the upcoming fiscal year[164]. Corporate Governance - The board consists of 9 directors, including 3 independent directors, ensuring compliance with governance regulations[155]. - The supervisory board has 3 members, including 1 employee representative, to ensure independent oversight of company operations[156]. - The company is committed to maintaining high corporate governance standards to protect shareholder interests[155]. - The company has not faced any penalties from securities regulatory authorities in the past three years[175]. - The company’s profit distribution principles align with regulatory requirements, ensuring protection of shareholder interests, particularly for minority investors[192]. Strategic Initiatives - The company aims to optimize its industrial structure and deepen its business development in the intelligent material management sector, targeting the smart medical project business segment[41]. - The company plans to enhance collaboration between upstream and downstream industries to improve operational efficiency and product development[151]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[164]. - The company plans to implement new marketing strategies aimed at increasing brand awareness and customer engagement, with a budget allocation of 50 million RMB[171]. - The company aims to improve operational efficiency, targeting a 15% reduction in costs through process optimization initiatives[171].

苏州艾隆科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 2022 年第一季度报告 证券代码：688329 证券简称：艾隆科技 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 43,109,552.26 | 7.91 | | 归属于上市公司股东的净利润 | | -393,057.54 | -106.67 | | 归属于上市公司股东的扣除非 | | -1,85 ...

2021 年第三季度报告 证券代码：688329 证券简称：艾隆科技 苏州艾隆科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 76,909,851.78 | 16.99 | 207,372,660.68 | 32.83 ...

2021 年半年度报告 公司代码：688329 公司简称：艾隆科技 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 苏州艾隆科技股份有限公司 2021 年半年度报告 1 / 204 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报 告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对 措施，敬请查阅本报告"第三节管理层讨论与分析"之"五、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 无 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实 质承诺，敬请投资者注意投资风险。 九、 是否存在被控股股东及其关联方非经营性占用资金情况 否 2 / 204 四、 本半年度报告未经审计。 五、 公司负责人张银花、主管会计工作负责人李万凤及会计机构负责人 （会计主管人员）李万凤声明：保证半年度报告中财务报告的真实、准 确、完整。 六、 董事会决议通过的本报告期 ...

2020 年年度报告 公司代码：688329 公司简称：艾隆科技 苏州艾隆科技股份有限公司 2020 年年度报告 1 / 194 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅本报告"第四节经营情况讨论与分析"之"二、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 五、 公司负责人张银花、主管会计工作负责人李万凤及会计机构负责人（会计主管人员）李万凤 声明：保证年度报告中财务报告的真实、准确、完整。 六、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经董事会决议，公司2020年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润 。本次利润分配方案为：公司拟向全体股东每10股派发现金红利3元（含税）。截至2021年3月31 日，公司总股本77,200,000股，以 ...